Samuel F Berkovic1, John F Staropoli2, Stirling Carpenter2, Karen L Oliver2, Stanislav Kmoch2, Glenn W Anderson2, John A Damiano2, Michael S Hildebrand2, Katherine B Sims2, Susan L Cotman2, Melanie Bahlo2, Katherine R Smith2, Maxime Cadieux-Dion2, Patrick Cossette2, Ivana Jedličková2, Anna Přistoupilová2, Sara E Mole. 1. From the Epilepsy Research Centre, Department of Medicine (S.F.B., K.L.O., J.A.D., M.S.H.), University of Melbourne, Austin Health, Heidelberg, Australia; Biogen, Inc. (J.F.S.), Cambridge, MA; Department of Pathology (S.C.), Centro Hospitalar São João, Porto, Portugal; Institute of Inherited Metabolic Disorders (S.K., I.J., A.P.), First Faculty of Medicine, Charles University in Prague; General University Hospital in Prague (S.K.), Czech Republic; Great Ormond Street Hospital for Children NHS Foundation Trust (G.W.A.), London, UK; Center for Human Genetic Research and Department of Neurology (K.B.S., S.L.C.), Harvard Medical School, Massachusetts General Hospital, Boston; Population Health and Immunity Division (M.B., K.R.S.), The Walter and Eliza Hall Institute of Medical Research; Departments of Mathematics and Statistics and Medical Biology (M.B.), University of Melbourne, Australia; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (M.C.-D., P.C.), University of Montreal, Canada; and MRC Laboratory for Cell Biology (S.E.M.), Department of Genetics, Evolution & Environment and UCL Institute of Child Health, University College London, UK. s.berkovic@unimelb.edu.au. 2. From the Epilepsy Research Centre, Department of Medicine (S.F.B., K.L.O., J.A.D., M.S.H.), University of Melbourne, Austin Health, Heidelberg, Australia; Biogen, Inc. (J.F.S.), Cambridge, MA; Department of Pathology (S.C.), Centro Hospitalar São João, Porto, Portugal; Institute of Inherited Metabolic Disorders (S.K., I.J., A.P.), First Faculty of Medicine, Charles University in Prague; General University Hospital in Prague (S.K.), Czech Republic; Great Ormond Street Hospital for Children NHS Foundation Trust (G.W.A.), London, UK; Center for Human Genetic Research and Department of Neurology (K.B.S., S.L.C.), Harvard Medical School, Massachusetts General Hospital, Boston; Population Health and Immunity Division (M.B., K.R.S.), The Walter and Eliza Hall Institute of Medical Research; Departments of Mathematics and Statistics and Medical Biology (M.B.), University of Melbourne, Australia; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (M.C.-D., P.C.), University of Montreal, Canada; and MRC Laboratory for Cell Biology (S.E.M.), Department of Genetics, Evolution & Environment and UCL Institute of Child Health, University College London, UK.
Abstract
OBJECTIVE: To critically re-evaluate cases diagnosed as adult neuronal ceroid lipofuscinosis (ANCL) in order to aid clinicopathologic diagnosis as a route to further gene discovery. METHODS: Through establishment of an international consortium we pooled 47 unsolved cases regarded by referring centers as ANCL. Clinical and neuropathologic experts within the Consortium established diagnostic criteria for ANCL based on the literature to assess each case. A panel of 3 neuropathologists independently reviewed source pathologic data. Cases were given a final clinicopathologic classification of definite ANCL, probable ANCL, possible ANCL, or not ANCL. RESULTS: Of the 47 cases, only 16 fulfilled the Consortium's criteria of ANCL (5 definite, 2 probable, 9 possible). Definitive alternate diagnoses were made in 10, including Huntington disease, early-onset Alzheimer disease, Niemann-Pick disease, neuroserpinopathy, prion disease, and neurodegeneration with brain iron accumulation. Six cases had features suggesting an alternate diagnosis, but no specific condition was identified; in 15, the data were inadequate for classification. Misinterpretation of normal lipofuscin as abnormal storage material was the commonest cause of misdiagnosis. CONCLUSIONS: Diagnosis of ANCL remains challenging; expert pathologic analysis and recent molecular genetic advances revealed misdiagnoses in >1/3 of cases. We now have a refined group of cases that will facilitate identification of new causative genes.
OBJECTIVE: To critically re-evaluate cases diagnosed as adult neuronal ceroid lipofuscinosis (ANCL) in order to aid clinicopathologic diagnosis as a route to further gene discovery. METHODS: Through establishment of an international consortium we pooled 47 unsolved cases regarded by referring centers as ANCL. Clinical and neuropathologic experts within the Consortium established diagnostic criteria for ANCL based on the literature to assess each case. A panel of 3 neuropathologists independently reviewed source pathologic data. Cases were given a final clinicopathologic classification of definite ANCL, probable ANCL, possible ANCL, or not ANCL. RESULTS: Of the 47 cases, only 16 fulfilled the Consortium's criteria of ANCL (5 definite, 2 probable, 9 possible). Definitive alternate diagnoses were made in 10, including Huntington disease, early-onset Alzheimer disease, Niemann-Pick disease, neuroserpinopathy, prion disease, and neurodegeneration with brain iron accumulation. Six cases had features suggesting an alternate diagnosis, but no specific condition was identified; in 15, the data were inadequate for classification. Misinterpretation of normal lipofuscin as abnormal storage material was the commonest cause of misdiagnosis. CONCLUSIONS: Diagnosis of ANCL remains challenging; expert pathologic analysis and recent molecular genetic advances revealed misdiagnoses in >1/3 of cases. We now have a refined group of cases that will facilitate identification of new causative genes.
Authors: Eon Joo Park; Kariona A Grabińska; Ziqiang Guan; Viktor Stránecký; Hana Hartmannová; Kateřina Hodaňová; Veronika Barešová; Jana Sovová; Levente Jozsef; Nina Ondrušková; Hana Hansíková; Tomáš Honzík; Jiří Zeman; Helena Hůlková; Rong Wen; Stanislav Kmoch; William C Sessa Journal: Cell Metab Date: 2014-07-24 Impact factor: 27.287
Authors: Roberto Di Fabio; Francesca Moro; Liliana Pestillo; Maria C Meschini; Francesco Pezzini; Stefano Doccini; Carlo Casali; Francesco Pierelli; Alessandro Simonati; Filippo M Santorelli Journal: Neurology Date: 2014-10-01 Impact factor: 9.910
Authors: Mikko Muona; Samuel F Berkovic; Leanne M Dibbens; Karen L Oliver; Snezana Maljevic; Marta A Bayly; Tarja Joensuu; Laura Canafoglia; Silvana Franceschetti; Roberto Michelucci; Salla Markkinen; Sarah E Heron; Michael S Hildebrand; Eva Andermann; Frederick Andermann; Antonio Gambardella; Paolo Tinuper; Laura Licchetta; Ingrid E Scheffer; Chiara Criscuolo; Alessandro Filla; Edoardo Ferlazzo; Jamil Ahmad; Adeel Ahmad; Betul Baykan; Edith Said; Meral Topcu; Patrizia Riguzzi; Mary D King; Cigdem Ozkara; Danielle M Andrade; Bernt A Engelsen; Arielle Crespel; Matthias Lindenau; Ebba Lohmann; Veronica Saletti; João Massano; Michael Privitera; Alberto J Espay; Birgit Kauffmann; Michael Duchowny; Rikke S Møller; Rachel Straussberg; Zaid Afawi; Bruria Ben-Zeev; Kaitlin E Samocha; Mark J Daly; Steven Petrou; Holger Lerche; Aarno Palotie; Anna-Elina Lehesjoki Journal: Nat Genet Date: 2014-11-17 Impact factor: 38.330
Authors: O P van Diggelen; S Thobois; C Tilikete; M T Zabot; J L Keulemans; P A van Bunderen; P E Taschner; M Losekoot; Y V Voznyi Journal: Ann Neurol Date: 2001-08 Impact factor: 10.422
Authors: Ivana Jedličková; Maxime Cadieux-Dion; Anna Přistoupilová; Viktor Stránecký; Hana Hartmannová; Kateřina Hodaňová; Veronika Barešová; Helena Hůlková; Jakub Sikora; Lenka Nosková; Dita Mušálková; Petr Vyleťal; Jana Sovová; Patrick Cossette; Eva Andermann; Frederick Andermann; Stanislav Kmoch Journal: Eur J Hum Genet Date: 2020-01-09 Impact factor: 4.246
Authors: Alexandra Moreno-García; Alejandra Kun; Olga Calero; Miguel Medina; Miguel Calero Journal: Front Neurosci Date: 2018-07-05 Impact factor: 4.677
Authors: Guillermo Guelbert; Ana Clara Venier; Ines Adriana Cismondi; Adriana Becerra; Juan Carlos Vazquez; Elmer Andrés Fernández; Ana Lucía De Paul; Norberto Guelbert; Ines Noher; Favio Pesaola Journal: Front Neurol Date: 2022-08-12 Impact factor: 4.086